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Abstract To characterize primary failure to inﬂiximab
and determine the efﬁcacy of switching to tocilizumab in
patients with rheumatoid arthritis (RA), we examined 24 RA
patients who had started on inﬂiximab therapy (3 mg/kg) as
their ﬁrst biological agent. Nine of the 24 patients were
found to be primary nonresponders, deﬁned as patients who
had never achieved a 20% clinical improvement accord-
ing to the American College of Rheumatology criteria
(ACR20) during induction therapy. The remaining 15
patients had achieved an ACR20 response to inﬂiximab,
without any relapses, for at least the ﬁrst 14 weeks. A
higher baseline health assessment questionnaire score was
markedly associated with primary unresponsiveness to
inﬂiximab (p = 0.0005). Six of the 9 primary nonre-
sponders showed rapid clearance of inﬂiximab: their trough
concentrations of inﬂiximab were under 1 lg/ml. The other
3 were classiﬁed as exhibiting the residual type of unre-
sponsiveness, which was deﬁned as unresponsiveness in
patients who maintained serum inﬂiximab levels above
1 lg/ml. Human antichimeric antibody was not detected
in the rapid-clearance nonresponders. Dose escalation
(5 mg/kg) was insufﬁciently effective. Primary nonre-
sponders to inﬂiximab were started on tocilizumab therapy
(8 mg/kg, every 4 weeks), and their responses were
assessed after 24 weeks of this second attempt at therapy.
All the nonresponders, except for a single rapid-clearance
patient, had achieved an ACR20 clinical improvement at the
time of assessment. In conclusion, primary nonresponders to
inﬂiximab can be classiﬁed into rapid-clearance and residual
types, based on their trough concentrations of inﬂiximab, but
both types of nonresponders seem to beneﬁt from an early
decision to discontinue inﬂiximab therapy and switch to
tocilizumab.
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Introduction
The prognosis of rheumatoid arthritis (RA) has improved
dramatically with the development of novel therapeutic
strategies targeted at speciﬁc cytokines such as tumor
necrosis factor-a (TNFa), but we have learned through
daily practice that not all RA patients treated with anti-
TNFa agents show good therapeutic responses. Trial
studies have also shown that approximately 30% of indi-
viduals who try these agents fail to achieve a 20% clinical
improvement according to the American College of
Rheumatology criteria (ACR20) [1–3]. Recent studies have
identiﬁed two types of lack of efﬁcacy that can bring about
the failure of anti-TNFa therapy [4–6]. One is the absence
of any clinical response (primary lack of efﬁcacy); the
other is the disappearance of an initial favorable response
during therapy (secondary loss of efﬁcacy). It has been
suggested that switching to an alternative anti-TNFa agent
may be less effective in nonresponders who showed a
primary lack of efﬁcacy than in those in whom the ﬁrst
anti-TNFa agent was withdrawn due to a secondary loss of
efﬁcacy [7–9]. To date, however, we lack reliable guide-
lines for choosing alternative treatments for individual RA
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[10, 11]. Therapeutic decisions regarding switching therefore
depend on individual rheumatologists’ experience, patients’
preferences, and the risks associated with individual drugs.
Encouraging data from recent phase-III trials of toc-
ilizumab, a humanized monoclonal anti-interleukin (IL)-6
receptor (IL-6R) antibody, have led to its approval in
Japan, Europe, and the United States for the treatment of
patients with moderate to severe RA showing inadequate
response to conventional disease-modifying anti-rheumatic
drugs (DMARDs) and anti-TNFa agents [12]. Approxi-
mately 60–80% of DMARD-resistant patients in the group
receiving 8 mg/kg of tocilizumab every 4 weeks achieved
an ACR20 at 24 weeks [13–15]. In one large study lasting
for 52 weeks, patients in the tocilizumab-treated group had
signiﬁcantly less radiographic progression than those
treated with conventional DMARDs [16]. Furthermore,
Emery et al. [17] have shown that an ACR20 was achieved
at 24 weeks by 50% of patients in the tocilizumab-treated
group who had inadequate response to one or more anti-
TNFa agents, although the type of failure of anti-TNFa
therapy in individual patients was not determined.
Kawashiri et al. [18] have reported that tocilizumab induced
remarkable clinical responses in secondary nonresponders to
anti-TNFa agents. The remaining question is how primary
nonresponderstoanti-TNFaagentsmaybeneﬁtfromaswitch
to this new biological agent with its different mechanism of
action.
The detailed mechanisms underlying primary failure to
inﬂiximab, a chimeric anti-TNFa monoclonal antibody, are
poorly understood. Since several studies have suggested
that favorable therapeutic outcomes depend in part on
sufﬁcient exposure to inﬂiximab during the course of
therapy [19–22], it appears that the serum concentration of
inﬂiximab at the end of a dosing period (trough concen-
tration) may be a useful clue in exploring the mechanisms
of primary failure. Here, we report on 9 patients with RA
who showed a primary lack of efﬁcacy of inﬂiximab. To
identify the responsible mechanisms, we measured serum
trough concentrations of inﬂiximab and examined the for-
mation of human antichimeric antibody (HACA) in sera.
We also assessed the efﬁcacy of switching to tocilizumab
in primary inﬂiximab-nonresponders, based on the ACR
improvement criteria and the European League Against
Rheumatism (EULAR) response criteria.
Patients, materials, and methods
Patients, study protocol, and evaluation
From June 2009 to June 2010, we initiated inﬂiximab
therapy in 24 patients with RA at Kumamoto Saishunsou
National Hospital, who had never previously received any
biological agent. All participants fulﬁlled the 1987 ACR
criteria for a diagnosis of RA. Eligibility for inﬂiximab
therapy was determined according to the revised guidelines
ofﬁcially approved by the Japan College of Rheumatology
(JCR) in 2008: namely, a patient is eligible for consider-
ation of inﬂiximab therapy if RA is inadequately controlled
despite treatment for at least 3 months with standard doses
of conventional DMARDs, usually methotrexate (MTX,
more than 6 mg/week); inadequate control is deﬁned as the
presence of 6 or more tender joints, 6 or more swollen
joints, and either an erythrocyte sedimentation rate (ESR)
equal to or higher than 28 mm/h or C-reactive protein
(CRP) level equal to or higher than 2 mg/dl. In addition,
patients with radiographic progression, deﬁned as an
increase of the total Sharp score by more than 10 points per
year, and those with a disease activity score for 28 joints
(DAS28 score) equal to or greater than 3.2, were also
considered eligible for inﬂiximab therapy.
Patients were scheduled to receive a 3-infusion induc-
tion regimen, consisting of intravenous infusions of inf-
liximab (3 mg/kg) at weeks 0, 2, and 6. During inﬂiximab
therapy, 8 mg/week of MTX and 5 mg/week of folic acid
were given concomitantly. Patients who were receiving
prednisolone at the start of inﬂiximab therapy continued to
receive the same dose of prednisolone concomitantly
throughout the period of inﬂiximab therapy (2 patients
receiving 10 mg/day and 2 receiving 5 mg/day). Clinical
responses were evaluated according to the ACR improve-
ment criteria and the EULAR response criteria. Primary
nonresponders were deﬁned as patients who never achieved
an ACR20 response during this therapy. The type of pri-
mary failure in each patient was determined based on
trough serum concentrations of inﬂiximab immediately
before each infusion. The residual type of unresponsive-
ness was deﬁned as unresponsiveness in patients who
maintained serum inﬂiximab levels above 1 lg/ml; a lack
of efﬁcacy due to rapid clearance was deﬁned as unre-
sponsiveness in patients whose trough concentrations of
inﬂiximab were under 1 lg/ml. The primary nonrespond-
ers, with two exceptions, stopped inﬂiximab therapy before
the fourth infusion; the two exceptions were both patients
with rapid clearance (cases 1 and 4) for whom we changed
the dose to 5 mg/kg at the fourth infusion (dose escalation)
and determined serum trough concentrations and clinical
responses 8 weeks later. Patients who had achieved and
maintained an ACR20 response by week 14 started main-
tenance therapy with 3 mg/kg of inﬂiximab every 8 weeks.
All patients exhibiting primary lack of efﬁcacy of inf-
liximab were switched to tocilizumab therapy (intravenous
infusion of 8 mg/kg every 4 weeks for 24 weeks). MTX
(8 mg/week) and 5 mg/week of folic acid were given con-
comitantly. Clinical responses were evaluated according to
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criteria. Disease activity was measured according to the
DAS28 score, which was calculated based on a swollen
joint count in the 28 joints (SJC28), a tender joint count in
the 28 joints (TJC28), ESR, and the patients’ own global
evaluation of their general health on a visual analog scale
(VAS, scale of 0–100). Serum CRP levels, Health Assess-
ment Questionnaire (HAQ) score, SJC66, and TJC68 were
also recorded.
The ethics committee of Kumamoto Saishunsou
National Hospital approved the protocol for this study, and
written informed consent was obtained from all patients.
Inﬂiximab serum assay and HACA detection
Blood samples were collected immediately prior to each
infusion. Serum trough concentrations of inﬂiximab were
measured through an enzyme-linked immunosorbent assay
(ELISA) using a monoclonal antibody speciﬁc to the TNFa
binding site [23]. The captured inﬂiximab was detected by
a biotinylated monoclonal antibody speciﬁc for an epitope
in its variable region. The lowest level that could reliably
be detected was 0.1 lg/ml. HACA was measured using a
modiﬁed version of the ELISA method originally reported
by LoBuglio et al. [24], when the lowest serum concen-
trations of inﬂiximab were below the detectable limit of the
assays.
Measurements of tocilizumab
Serum trough concentrations of tocilizumab were mea-
sured through an ELISA using a mouse anti-IL-6R
monoclonal antibody (MT-18) in combination with human
soluble IL-6R [25]. The captured tocilizumab was detected
by a biotinylated monoclonal antibody speciﬁc for an
epitope in its variable region. The lowest concentration that
could reliably be detected was 1.0 lg/ml. This assay was
performed at SRL (Tachikawa, Japan).
Measurements of anti-cyclic citrullinated peptide
antibodies (anti-CCP Abs) and IgM rheumatoid factor
(RF)
Sera that had been collected at the start and end of each
course of therapy and stored at -80C were examined for
concentrations of anti-CCP Abs and IgM RF. Anti-CCP
Abs were measured using a commercially available ELISA
kit (anti-CCP2 assay; Axis-Shield Diagnostic, Dundee,
Scotland) according to the manufacturer’s instructions. The
concentrations of anti-CCP Abs were estimated by inter-
polating from a standard dose–response curve. A serum
sample was considered to be anti-CCP-positive if its
absorbance value was greater than 4.6 U/ml. Anti-CCP
Abs were measured at SRL. IgM RF was measured by
means of nephelometry; a serum sample was considered to
be positive if the concentration was higher than the cut-off
value of the kit (15 IU/ml).
Statistical analysis
In analyses of categorical variables, levels of signiﬁcance
were determined by means of the v
2test, using 2 9 2
contingency tables. If cell values were less than 5, Fisher’s
exact probability test was used. Continuous variables were
assessed using the Mann–Whitney U-test. For all tests,
probability (p) values of\0.05 were considered to indi-
cate statistical signiﬁcance. All calculations were per-
formed using Excel Statistical Analysis 2008 (SSRI,
Tokyo, Japan).
Results
Baseline characteristics of RA patients showing
a primary lack of efﬁcacy
Among the 24 patients who received inﬂiximab therapy, 9
were characterized by a primary lack of efﬁcacy of inf-
liximab. During the induction regimen of inﬂiximab, these
primary nonresponders exhibited no response and never
achieved an ACR20 response. The remaining 15 patients
did achieve an ACR20 response to inﬂiximab (3 patients
with ACR20; 7 with ACR50; and 5 with ACR70) and had
no relapses for at least the ﬁrst 14 weeks. When clinical
responses to inﬂiximab were evaluated according to the
EULAR response criteria, 15 patients had achieved a good
or moderate response (7 patients with a good response and
8 with a moderate response). One patient who was classi-
ﬁed as a nonresponder according to the ACR criteria had
achieved a moderate response according to the EULAR
response criteria, and one patient who was classiﬁed into
the responder group according to the ACR criteria had
failed to achieve a good or moderate EULAR response. As
shown in Table 1, males were more likely to show a pri-
mary lack of efﬁcacy (p = 0.047). A higher baseline HAQ
score was markedly associated with primary unrespon-
siveness to inﬂiximab therapy (p = 0.0005). Initial levels
of DAS28 and ESR were also signiﬁcantly higher in the
primary nonresponders compared with the responder group
(p = 0.04).
Demographic and clinical data of the primary nonre-
sponders at the start of inﬂiximab therapy are shown in
Table 2. There were ﬁve cases of early RA (3–14 months)
that had presented with abrupt-onset acute polyarthritis
(cases 2–6); the other 4 were long-standing RA cases
(3–10 years) showing a progressive pattern of the clinical
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liximab therapy, all nonresponders had received 8 mg/
week of MTX and 2 patients had also received 10 mg/day
of prednisolone; nevertheless, their disease activity had
remained high and they had complained of intense joint
pain, diffuse swelling, and difﬁculty in performing activi-
ties of daily living.
Characterization of primary lack of efﬁcacy based
on trough concentrations of inﬂiximab
In the nonresponders, the number of joints involved actu-
ally increased during induction therapy with inﬂiximab
(Table 3). Indices of disease activity and disability had
deteriorated. In 6 patients (cases 1–6), trough concentra-
tions of serum inﬂiximab were below the therapeutic level
(1 lg/ml) (Fig. 1). Among these, cases 1 and 4 had
received a dose escalation at the fourth infusion (5 mg/kg
of inﬂiximab at week 14), but they nevertheless showed
undetectably low trough concentrations (less than 0.1 lg/ml).
HACA was not detected in any of the patients whose
lowest serum concentrations of inﬂiximab were below
the detectable limit of the assays. In contrast, the other
3 patients (cases 7–9) had maintained serum inﬂiximab
levels sufﬁciently high to produce therapeutic effects.
As shown in Fig. 1, approximately 80% of the respond-
ers maintained serum concentrations of inﬂiximab above
1 lg/ml, even immediately before the 4th infusion. We
concluded that all nonresponders were characterized by a
primary lack of efﬁcacy of inﬂiximab. Rapid clearance was
the main cause of failure in cases 1–6, while the other cases
were classiﬁed as the residual type. We decided to switch
the patients from inﬂiximab to tocilizumab.
Therapeutic effects of switching to tocilizumab
in primary nonresponders to inﬂiximab
The primary nonresponders to inﬂiximab started toc-
ilizumab therapy in combination with MTX. Twenty-four
weeks after making this switch, all the nonresponders,
except for case 6, had achieved a good or moderate response
as deﬁned by the EULAR criteria and a 20, 50, or 70%
clinical improvement as deﬁned by the ACR criteria, as
shown in Table 4. Four patients had achieved clinical
remission (cases 3–5 and 9).Case 6had transientlyachieved
an ACR20 response at week 16 but had subsequently
relapsed. At week 24, this patient’s trough concentration of
serum tocilizumab was still detectable (2.3 lg/ml) and no
anti-tocilizumab antibody was observed.
Discussion
In 6 patients in the present study (cases 1–6), unrespon-
siveness to inﬂiximab therapy was characterized by a pri-
mary lack of efﬁcacy due to rapid clearance. These patients
Table 1 Baseline characteristics of RA patients
Total (n = 24) Primary nonresponders (n = 9) Responders (n = 15) p*
Male/female 5/19 4/5 1/14 0.047
Age, years, median (25th, 75th percentiles) 61.5 (58, 70) 69 (63, 70) 59 (57.5, 62.5) 0.07
RA duration, months, median (25th, 75th percentiles) 19.5 (5, 54.3) 14 (5, 108) 24 (6, 44) 0.90
DAS28-ESR, median (25th, 75th percentiles) 5.7 (5.1, 6.4) 6.1 (5.7, 6.8) 5.3 (4.8, 5.8) 0.040
HAQ, median (25th, 75th percentiles) 0.81 (0.59, 1.78) 1.87 (1.65, 2.25) 0.63 (0.44, 0.75) 0.0005
CRP, mg/dl, median (25th, 75th percentiles) 1.9 (0.7, 3.3) 2.1 (2.0, 6.0) 1.0 (0.5, 2.7) 0.08
ESR, mm/h, median (25th, 75th percentiles) 41.5 (26, 73) 52 (42, 93) 38 (25, 56.5) 0.042
Positive anti-CCP Abs, numbers of patients (%) 23 (95.6) 8 (88.9) 15 (100) 0.38
Positive IgM RF, numbers of patients (%) 22 (91.7) 7 (77.8) 15 (100) 0.13
SJC66, median (25th, 75th percentiles) 7.5 (5, 12) 10 (6, 13) 6 (4.5, 10.5) 0.49
TJC68, median (25th, 75th percentiles) 10.5 (5, 17.5) 13 (5, 17) 9 (4.5, 11.5) 0.11
Use of MTX (8 mg/week), numbers of patients 24
a 91 5
a –
Use of folic acid (5 mg/week), numbers of patients 24
b 9
b 15 –
Use of PSL, numbers of patients (dose) 4 2 (10 mg/day) 2 (5 mg/day) –
Data were obtained at the time of enrollment
RA rheumatoid arthritis, DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR
erythrocyte sedimentation rate, anti-CCP Abs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC66 swollen joint count in 66
joints, TJC68 tender joint count in 68 joints, MTX methotrexate, PSL prednisolone
a Two patients had received 6 mg/week of MTX before the introduction of inﬂiximab therapy
b One patient had received 10 mg/week of folic acid
* p values are based on comparison between primary nonresponders and responders to inﬂiximab therapy
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above 1 lg/ml during 14 weeks of induction therapy.
Several groups have shown that trough serum concentra-
tions of inﬂiximab are related to clinical improvement in
RA and that the lower limit of the therapeutic level is
approximately 1 lg/ml [19–22]. Furthermore, we have
shown that, during 14 weeks of inﬂiximab therapy at
3 mg/kg via intravenous infusion, most good and moderate
responders exhibited trough concentrations greater than
1 lg/ml [4]. The drug’s rapid clearance may be explained
by high levels of TNFa production, since it is possible that
TNFa-inﬂiximab complexes are eliminated from the cir-
culation at a higher rate than unbound inﬂiximab molecules
are [4, 21]. A revival of TNFa-producing cells and a sub-
sequent overproduction of TNFa during inﬂiximab therapy
may induce a rapid clearance of inﬂiximab from the body.
For patients with high disease activity, therefore, we need
to pay special attention to trough concentrations of inﬂix-
imab. It has been reported that HACA formation may
possibly alter the pharmacokinetics of inﬂiximab [23], but
HACA was not detected in any patients who had shown a
rapid clearance of inﬂiximab in the present study, sug-
gesting that the rapid clearance observed here was not due
to the formation of anti-inﬂiximab antibodies. Given that a
dose–response relationship exists, dose escalation may be
beneﬁcial in some cases of this type. Two randomized,
Table 2 Demographic and clinical characteristics of primary nonresponders at the time of starting inﬂiximab therapy
Case
no.
Age
(years)/sex
RA duration
(months)
DAS28-
ESR
HAQ CRP
(mg/dl)
ESR
(mm/h)
Anti-CCP
Abs (U/ml)
IgM RF
(IU/ml)
SJC28
(SJC66)
TJC28
(TJC68)
1 70/F 36 6.7 1.75 2.9 52 591 255 5 (6) 16 (17)
2 36/F 5 6.9 2.25 1.1 42 Negative Negative 13 (28) 16 (31)
3 61/M 3 7.1 2.75 13.3 96 145 404 9 (10) 13 (23)
4 69/M 14 5.7 2.00 10.8 77 98 Negative 5 (7) 3 (5)
5 65/M 4 5.7 1.00 2.0 43 75 120 5 (5) 5 (5)
6 79/M 7 6.1 3.00 6.0 93 1710 258 5 (13) 4 (12)
7 71/F 108 6.8 1.87 2.1 96 24 Positive 8 (15) 8 (15)
8 70/F 120 5.1 1.65 2.0 26 22 21 5 (13) 5 (13)
9 63/F 112 5.3 0.87 0.6 40 655 Positive 1 (1) 5 (5)
Data were obtained immediately before starting inﬂiximab therapy
RA rheumatoid arthritis, DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR
erythrocyte sedimentation rate, anti-CCP Abs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC28 swollen joint count in 28
joints, TJC28 tender joint count in 28 joints
Table 3 Characterization of failure of inﬂiximab therapy in primary nonresponders
Case
no.
Trough
(lg/ml)
a
DAS28-
ESR
HAQ CRP
(mg/dl)
ESR
(mm/h)
Anti-CCP
Abs (U/ml)
IgM RF
(IU/ml)
SJC28
(SJC66)
TJC28
(TJC68)
EULAR
response
Reason for
lack of efﬁcacy
1 \0.1 7.2 2.63 3.8 65 907 86 13 (13) 13 (23) None Rapid clearance
2 \0.1 8.6 2.75 11.7 91 Negative Negative 22 (40) 24 (46) None Rapid clearance
3 \0.1 7.2 3.00 8.4 81 112 404 10 (17) 12 (19) None Rapid clearance
4 \0.1 6.4 2.00 4.5 47 254 Negative 9 (11) 9 (11) None Rapid clearance
5 0.38 5.8 1.25 2.0 42 151 95 7 (7) 7 (7) None Rapid clearance
6 0.5 7.5 3.00 6.5 94 770 196 13 (25) 16 (28) None Rapid clearance
7
b 4.71 5.3 1.65 0.5 75 127 45 2 (15) 4 (16) Moderate Residual type
8 5.77 5.8 1.75 2.0 38 Negative 21 3 (9) 7 (16) None Residual type
9 7.11 6.1 1.50 0.5 30 464 134 9 (9) 10 (12) None Residual type
DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR erythrocyte sedimentation
rate, anti-CCP Abs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC28 swollen joint count in 28 joints, TJC28 tender joint
count in 28 joints, EULAR European League Against Rheumatism
a The trough concentrations in case 5 and those in cases 7 and 8 were obtained immediately before the 2nd and 4th infusions of inﬂiximab,
respectively; those in the other patients were obtained immediately before the 3rd infusion. Values of the other markers were determined at the
end of inﬂiximab therapy
b Case 7 achieved a moderate response as deﬁned by the EULAR criteria at week 14, but failed to achieve a 20% clinical improvement as
deﬁned by the American College of Rheumatology (ACR) criteria
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123double-blind studies (the RISING and START studies)
have demonstrated that a considerable proportion of
patients showed better clinical responses after receiving
dose escalation of inﬂiximab, without an increased risk of
adverse events [19, 22]. In the present study, two patients
with rapid clearance received a dose escalation (5 mg/kg)
at week 14, but trough concentrations were still undetec-
tably low and no clinical improvement was observed. In
such cases, shortening the dosing interval could be an
alternative means of improving clinical responses to inf-
liximab therapy [20, 21]. Based on a randomized, double-
blind study, however, Pavelka et al. [26] have indicated
that dose escalation did not improve therapeutic efﬁcacy
for RA. In a systematic review and meta-analysis of ran-
domized, controlled trials for two licensed anti-TNF anti-
bodies, Bongartz et al. [27] reported a dose-dependent
increased risk of malignancies; nevertheless, a recent sys-
tematic review of data from the United States, Canadian,
Swedish, German, Spanish, and British registries and data
from long-term, open-label extension studies has shown no
increase in the overall risk of malignancy in patients
exposed to anti-TNFa therapy [28]. Longitudinal con-
trolled studies may be needed to more precisely determine
the efﬁcacy and safety of dose escalation in inﬂiximab
therapy for RA.
In the present study, we also observed 3 patients
showing the residual type of unresponsiveness to inﬂix-
imab therapy (cases 7–9). Throughout the course of inf-
liximab therapy, these patients maintained sufﬁcient levels
of serum inﬂiximab, yet still exhibited a primary lack of
efﬁcacy. This type of primary unresponsiveness has rarely
been documented. In such cases, TNFa may not be the
main factor driving the inﬂammatory process in RA, or
alternative inﬂammatory pathways, such as IL-6 signaling,
may be utilized to evade the inhibitory effects of the anti-
TNFa agent. Either way, it seems rational to discontinue
inﬂiximab therapy in such cases. For primary nonre-
sponders to inﬂiximab without rapid clearance, it may be
helpful and cost-effective to switch to tocilizumab, because
these two biological agents target different molecules in the
inﬂammatory cascade of RA.
In the present study, 37.5% of RA patients had never
achieved an ACR20 response during induction therapy
with inﬂiximab; a good or moderate EULAR response was
achieved in 62.5% of patients. This rate of clinical
improvement in response to inﬂiximab was lower than that
seen in our previous study, in which 15 patients (83.3%)
0
8
2
4
6
10
I
n
f
l
i
x
i
m
a
b
 
t
r
o
u
g
h
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
µ
g
/
m
l
)
Responders Nonresponders
12
Fig. 1 Trough serum concentrations of inﬂiximab in the responder
group and the nonresponder group. Blood samples were collected
immediately before the 2nd infusion (open circle), the 3rd infusion
(closed circles), or the 4th infusion (closed squares) of inﬂiximab.
Nine patients in the responder group had available data. The broken
line indicates the lower limit of the therapeutic level (1 lg/ml)
Table 4 EULAR responses and ACR improvement in RA patients at the end of 24 weeks of tocilizumab therapy
Case
no.
DAS28-
ESR
HAQ CRP
(mg/dl)
ESR
(mm/h)
Anti-CCP
Abs (U/ml)
IgM RF
(IU/ml)
SJC28
(SJC66)
TJC28
(TJC68)
EULAR
response
ACR
improvement
1 4.0 0.62 \0.05 13 342 52 4 (11) 7(15) Moderate ACR20
2 3.4 0.75 \0.05 6 Negative Negative 0 (3) 9 (11) Moderate ACR70
3 2.4 0.25 \0.05 6 6 30 0 (0) 0 (2) Good ACR70
4 1.2 0.25 \0.05 3 124 Negative 1 (1) 0 (0) Good ACR70
5 2.2 0.25 \0.05 2 157 157 0 (0) 1 (1) Good ACR70
6 8.6 3.00 6.6 112 865 186 20 (40) 22 (42) None Refractory
7 3.6 0.50 \0.05 20 42 38 1 (1) 2 (3) Moderate ACR50
8 3.6 0.50 \0.05 20 Negative 29 1 (1) 2 (2) Moderate ACR50
9 1.8 0.25 \0.05 5 224 79 0 (0) 1 (1) Good ACR70
All patients had received tocilizumab for 24 weeks. Data were obtained 24 weeks after starting tocilizumab therapy
RA rheumatoid arthritis, DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR
erythrocyte sedimentation rate, anti-CCP Abs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC28 swollen joint count in 28
joints, TJC28 tender joint count in 28 joints, EULAR European League Against Rheumatism, ACR American College of Rheumatology
Mod Rheumatol (2011) 21:628–636 633
123had achieved a good or moderate response by week 14 of
therapy and only 3 patients were found to be nonresponders
[4]. Retrospective clinical studies by an RA management
group in Japan (the RECONFIRM and RECONFIRM II
studies) have shown that, by week 22 of inﬂiximab therapy,
84.5% of patients achieved a good or moderate EULAR
response [29, 30]. The RISING study, also conducted in
Japan, has reported that an ACR20 response was achieved
in 75.8% of patients by week 54 [22]. In Western countries,
however, a randomized controlled trial has shown that only
62.4% of MTX-naı ¨ve patients with early RA achieved an
ACR20 clinical improvement by week 54 [31]. Using
results from the British registry, Hyrich et al. [32] have
reported that 33% of RA patients exhibited no EULAR
response to inﬂiximab therapy after 6 months. Likewise,
Abe et al. have reported that the ACR20 improvement rate
at week 14 was only 61.2% in a Japanese clinical trial [33].
These ﬁgures are in keeping with the present data. A
considerable number of patients participating in this study
were referred to our hospital for management of RA
because they showed increases in joint involvement despite
MTX therapy or because their RA presented with abrupt,
acute polyarthritis; both of these are less common types of
RA. Considering our small sample size and relatively short
period of observation, we cannot exclude the possibility
that this referral bias may have inﬂuenced the response rate
to inﬂiximab.
A considerable number of observational studies have
shown that switching between anti-TNFa agents is bene-
ﬁcial for RA patients; however, the probability of achiev-
ing a sufﬁcient clinical response and the average magnitude
of response associated with sequential anti-TNFa treat-
ments are lower than those for ﬁrst-time anti-TNFa treat-
ments [34–36]. Data from the British registry show that the
reasons for failure of the ﬁrst anti-TNFa drug can recur
with the new drug after switching, and investigators have
identiﬁed a group of patients with multiple anti-TNFa
failures [37]. In a report based on the Swedish registry, the
therapeutic responses achieved by patients who switched
between anti-TNFa agents were limited compared with
those of anti-TNFa-naı ¨ve patients [38]. Similar conclusions
have been drawn based on the Spanish registry: the
response to a second or third anti-TNFa agent was much
smaller than the response to the ﬁrst one [39]. Furthermore,
it has not yet been established whether the type of failure
that motivated the switch from the ﬁrst anti-TNFa agent,
such as primary lack of efﬁcacy, secondary loss of efﬁcacy,
or adverse effects, inﬂuences the response to the new drug
[10, 11]. In the British, Swedish, and Spanish registries,
however, RA patients who had stopped a ﬁrst anti-TNFa
agent because of lack of efﬁcacy showed less extensive
improvements in response to a second agent than those
who had discontinued due to adverse effects [37, 38, 40].
In a recent review of the literature, Scrivo et al. [41] have
suggested that RA patients who withdrew a ﬁrst anti-TNFa
agent due to secondary failure or adverse effects may be
successfully treated with another anti-TNFa agent, whereas
patients with primary failure to a ﬁrst anti-TNFa agent may
ﬁnd that a different type of biological agent is the best
alternative.
In a previous study, we reported that for patients who
showed a rapid clearance of inﬂiximab, increased use of
prednisolone or MTX was beneﬁcial to achieve sufﬁcient
clinical responses [4]. At the time of that study, 6 mg/week
of MTX was considered the optimal dosage for RA patients
in Japan, and it was recommended that the maximum
dosage be restricted to 8 mg/week. Very recently, however,
dosages of up to 16 mg/week were approved in Japan;
accordingly, increasing the dosage of MTX may be one
therapeutic option for RA patients with rapid clearance of
inﬂiximab. Since the revised 2008 JCR guidelines for the
use of inﬂiximab have warned that prednisolone contrib-
utes to an increased risk of serious infection during inf-
liximab therapy, increasing the dosage of prednisolone is
not feasible in our current practice. We have also demon-
strated that tacrolimus, a suppressor of the activation of
antigen-speciﬁc T cells, induced good clinical responses
for RA patients who were characterized by the primary
lack of efﬁcacy for inﬂiximab, regardless of the presence or
absence of rapid clearance [4]. Besides targeting speciﬁc
cytokines such as TNFa and IL-6, it may be required to
focus on events upstream in the inﬂammatory cascade,
such as T-cell activation.
In the present study, no serious adverse events were
observed during the 24-week courses of tocilizumab ther-
apy; nevertheless, several issues related to the safety of
tocilizumab are worth mentioning here. The 2010 revised
version of the JCR ofﬁcial guidelines for the use of toc-
ilizumab has recommended that, when it is used for RA
patients with multiple risk factors for serious infections,
including advanced age, pulmonary comorbidities, pred-
nisolone use (more than 5 mg/day), long disease duration
(more than 10 years), and Steinbrocker class 3 or 4, its use
must be preceded by a careful assessment of the predictable
risks juxtaposed with the foreseeable beneﬁts. In addition,
rheumatologists should be aware that tocilizumab can mask
signs of infection such as fever and general fatigue and can
suppress elevations of inﬂammatory markers such as CRP
and ESR, thereby leading to delay in the diagnosis of
infectious diseases.
In the present study, the primary nonresponders were
classiﬁed into two groups, the rapid-clearance type and the
residual type, according to their trough concentrations of
inﬂiximab. Both types of primary nonresponders seem to
beneﬁt from switching to tocilizumab. Further research on
the therapeutic efﬁcacy of switching to a biological agent
634 Mod Rheumatol (2011) 21:628–636
123of a different class may offer guidance for individual RA
patients with primary failure to inﬂiximab when discon-
tinuation of this therapy is under consideration.
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